ANAVEX LIFE SCIENCES CORP.
NEW YORK, NY · CIK 0001314052 · Biotech · Public
Small-molecule CNS therapeutics targeting neurological diseases
anavex.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $11M
- 4 Form D · Apr 2014
- 150 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 30 granted · 10 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20102011201220132014
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $500,000 | |
| Private capital raised | Form D · SEC | $49,500 | |
| Private capital raised | Form D · SEC | $10,000 | |
| Private capital raised | Form D · SEC | $10,000,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2485 | Genialis, Inc. | — | $12M |
| 2486 | Borealis Biosciences | — | — |
| 2487 | PANOME BIO INC | — | $12M |
| 2488 | ANAVEX LIFE SCIENCES CORP. | — | $11M |
| 2489 | APPLIED GENETIC TECHNOLOGIES CORPORATION | — | $9.3M |
| 2490 | 3+2 PHARMA, LLC | — | — |
| 2491 | CELL DATA SCIENCES, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Alison AyersDirector
- John ChisholmDirector
- Cameron DurrantDirector
- Harvey LalachDirector · Executive Officer
- Sean LowryDirector
- Christopher MisslingDirector · Executive Officer
- Athanosios SkarpelosDirector
- George TidmarshDirector · Executive Officer
- David TousleyDirector
- Alexandre VamvakidesExecutive Officer
Patents
- Neurodevelopmental Disorder Therapygranted
- A19-144, A2-73 and Certain Anticholinesterase Inhibitor Compositions and Method for Anti-Seizure Therapyapplication
- ANAVEX2-73 For The Treatment Of Genetic Neurodevelopmental Disordersapplication
- ANAVEX2-73 For The Treatment Of Genetic Neurodevelopmental Disordersgranted
- A19-144, A2-73 and Certain Anticholinesterase Inhibitor Compositions and Method for Anti-Seizure Therapygranted
- ANAVEX2-73 For The Treatment Of Genetic Neurodevelopmental Disordersgranted
- Analgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereofgranted
- Optimized SIGMA-1 Agonist Method Of Responder Selection And Treatmentapplication
- A2-73 As A Therapeutic For Insomnia, Anxiety And Agitationapplication
- SIGMA-1 Receptor Agonist Systolic Blood Pressure Therapyapplication
- Optimized SIGMA-1 Agonist Method Of Responder Selection And Treatmentgranted
- A2-73 As A Therapeutic For Insomnia, Anxiety And Agitationgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.